Please login to the form below

Not currently logged in
Email:
Password:

Vedanta Biosciences appoints two new heads

Lisa Schopf and Erik Spek join the firm
Vedanta Biosciences Erik Spek

Vedanta Biosciences has appointed Lisa Schopf as head of preclinical development and Erik Spek as head of intellectual property.

Vedanta is advancing a pipeline of product candidates designed to treat autoimmune, inflammatory and infectious diseases using technology that mines the human microbiome for potent pharmaceutical products.

Schopf formerly served as the senior director of preclinical development at Kala Pharmaceuticals and has over 20 years of industry experience.

Spek joins from Epizyme, a clinical stage biopharmaceutical company focused on epigenetic targets, where he worked as director of intellectual property.

Bernat Olle, CEO of Vedanta Biosciences, said: “We are delighted to welcome Lisa and Erik to the team. This is an exiting time for Vedanta, and their experience and leadership will be invaluable as we advance our pipeline of drug candidates and scale our discovery platform.”

14th October 2015

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

When is an agency not an agency?
The PR Week UK Top 150 Consultancies prompts anticipation and curiosity. But can a virtual collective of freelancers fairly be compared and ranked against conventional agencies?...
Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...